ストックスクリーナーアプリを入手
17.00
0.18%
0.03
前日終値:
$16.97
開ける：
$17.12
24時間の取引高:
129.67K
Relative Volume:
0.40
時価総額：
$631.45M
収益：
$11.88M
当期純損益:
$-162.08M
株価収益率:
-1.3617
EPS:
-12.484
ネットキャッシュフロー:
$-156.43M
1週間 パフォーマンス:
+1.86%
1か月 パフォーマンス:
+4.29%
6か月 パフォーマンス:
+36.11%
1年 パフォーマンス:
+15.65%
1日の値動き範囲:
$16.87
$17.66
1週間の範囲:
$16.03
$17.66
52週間の値動き範囲:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Compare CBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
17.00 | 602.85M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Piper Sandler | Overweight |
| 2026-01-21 | 開始されました | Guggenheim | Buy |
| 2025-08-25 | 開始されました | Jefferies | Buy |
| 2025-08-11 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-14 | 開始されました | Wedbush | Outperform |
| 2025-06-25 | 開始されました | Stifel | Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 開始されました | Noble Capital Markets | Outperform |
| 2024-07-26 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-22 | 開始されました | CapitalOne | Overweight |
| 2021-11-12 | アップグレード | Jefferies | Hold → Buy |
| 2021-04-29 | 再開されました | Stephens | Overweight |
| 2021-02-10 | 開始されました | Piper Sandler | Overweight |
| 2020-05-21 | 開始されました | Raymond James | Outperform |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-08-05 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | ダウングレード | SunTrust | Buy → Hold |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-04 | 開始されました | Oppenheimer | Outperform |
| 2018-12-18 | 開始されました | H.C. Wainwright | Buy |
| 2018-02-12 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-12-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 開始されました | Chardan Capital Markets | Buy |
| 2017-06-06 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-07-26 | 開始されました | SunTrust | Buy |
| 2016-06-30 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-17 | 繰り返されました | Stifel | Buy |
すべてを表示
Crescent Biopharma Inc (CBIO) 最新ニュース
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma Q2 Results: EPS beats estimates, losses narrow - scanx.trade
Exome Asset Management LLC Makes New $2.81 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
Crescent Biopharma (CBIO) Faces Selling Pressure, Testing Key Support After 4.29% DeclineTechnical Analysis - dars.gov.et
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Crescent Biopharma grants inducement stock options for 52,500 shares at $15.83 each - Bitget
Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers Positive Surprise as Pipeline Progress ContinuesRevenue Inflection Point - vinanet.vn
CBIO Options Volatility — NASDAQ:CBIO - TradingView
Jennison Associates LLC Invests $2.81 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million - Bitget
Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility - Kavout | AI
Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants - Stock Titan
Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal - Stock Titan
CBIO Q1 2026 Earnings: Better-than-Expected Loss as Biotech Continues DevelopmentInvestor Earnings Call - vinanet.vn
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Crescent Biopharma closes $143.7 million public offering - Investing.com
Crescent Biopharma closes $143.7 million public offering By Investing.com - Investing.com Nigeria
Crescent Biopharma (CBIO) Proxy filing Summary - Quartr
Press Release: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Moomoo
Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary - Quartr
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Hold Rating - Moomoo
Form 424B5 Crescent Biopharma Inc For: 15 July By Investing.com - Investing.com Canada
Crescent Bi raises up to $133.5M in registered offering of 8.09M shares and pre-funded warrants - TradingView
Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale - Stock Titan
Form 424B5 CRESCENT BIOPHARMA, INC. - StreetInsider
Crescent Biopharma Inc (CBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.07%
1.21%
大文字化:
|
ボリューム (24 時間):